Trial · NCT03910387
Adverse events30
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 30
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Blood and lymphatic system disorders | Blood and lymphatic system disorders | Group 1 (gemcitabine/nab-paclitaxel and telotristat ethyl) | 3 | 14 | 24 |
| other | Blood and lymphatic system disorders | Blood and lymphatic system disorders | Group 2 (gemcitabine/nab-paclitaxel) | 3 | 8 | 3 |
| other | Gastrointestinal disorders | Gastrointestinal disorders | Group 1 (gemcitabine/nab-paclitaxel and telotristat ethyl) | 8 | 14 | 17 |
| other | Gastrointestinal disorders | Gastrointestinal disorders | Group 2 (gemcitabine/nab-paclitaxel) | 1 | 8 | 1 |
| other | General disorders and administration site conditions | General disorders | Group 1 (gemcitabine/nab-paclitaxel and telotristat ethyl) | 9 | 14 | 20 |
| other | General disorders and administration site conditions | General disorders | Group 2 (gemcitabine/nab-paclitaxel) | 1 | 8 | 11 |
| other | Infections and infestations | Infections and infestations | Group 1 (gemcitabine/nab-paclitaxel and telotristat ethyl) | 0 | 14 | 0 |
| other | Infections and infestations | Infections and infestations | Group 2 (gemcitabine/nab-paclitaxel) | 1 | 8 | 2 |
| other | Injury, poisoning and procedural complications | Injury, poisoning and procedural complications | Group 1 (gemcitabine/nab-paclitaxel and telotristat ethyl) | 1 | 14 | 1 |
| other | Injury, poisoning and procedural complications | Injury, poisoning and procedural complications | Group 2 (gemcitabine/nab-paclitaxel) | 0 | 8 | 0 |
| other | Investigations | Investigations | Group 1 (gemcitabine/nab-paclitaxel and telotristat ethyl) | 4 | 14 | 52 |
| other | Investigations | Investigations | Group 2 (gemcitabine/nab-paclitaxel) | 0 | 8 | 0 |
| other | Metabolism and nutrition disorders | Metabolism and nutrition disorders | Group 1 (gemcitabine/nab-paclitaxel and telotristat ethyl) | 5 | 14 | 23 |
| other | Metabolism and nutrition disorders | Metabolism and nutrition disorders | Group 2 (gemcitabine/nab-paclitaxel) | 0 | 8 | 0 |
| other | Musculoskeletal and connective tissue disorders | Musculoskeletal and connective tissue disorders | Group 1 (gemcitabine/nab-paclitaxel and telotristat ethyl) | 1 | 14 | 1 |
| other | Musculoskeletal and connective tissue disorders | Musculoskeletal and connective tissue disorders | Group 2 (gemcitabine/nab-paclitaxel) | 0 | 8 | 0 |
| other | Nervous system disorders | Nervous system disorders | Group 1 (gemcitabine/nab-paclitaxel and telotristat ethyl) | 4 | 14 | 9 |
| other | Nervous system disorders | Nervous system disorders | Group 2 (gemcitabine/nab-paclitaxel) | 1 | 8 | 1 |
| other | Psychiatric disorders | Psychiatric disorders | Group 1 (gemcitabine/nab-paclitaxel and telotristat ethyl) | 2 | 14 | 3 |
| other | Psychiatric disorders | Psychiatric disorders | Group 2 (gemcitabine/nab-paclitaxel) | 0 | 8 | 0 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03910387/events